

# Jorge Vela-Ojeda

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6257280/publications.pdf>

Version: 2024-02-01

64  
papers

1,691  
citations

394421

19  
h-index

289244

40  
g-index

65  
all docs

65  
docs citations

65  
times ranked

2179  
citing authors

#	ARTICLE	IF	CITATIONS
1	Intermittent Target Inhibition With Dasatinib 100 mg Once Daily Preserves Efficacy and Improves Tolerability in Imatinib-Resistant and -Intolerant Chronic-Phase Chronic Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 3204-3212.	1.6	458
2	Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. <i>Haematologica</i> , 2010, 95, 232-240.	3.5	231
3	Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. <i>Leukemia</i> , 2012, 26, 1091-1097.	7.2	85
4	Is the international staging system superior to the Durie-Salmon staging system? A comparison in multiple myeloma patients undergoing autologous transplant. <i>Leukemia</i> , 2009, 23, 1528-1534.	7.2	81
5	Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis. <i>Annals of Hematology</i> , 2007, 86, 871-877.	1.8	58
6	Description of CD8 <sup>+</sup> Regulatory T Lymphocytes and Their Specific Intervention in Graft-versus-Host and Infectious Diseases, Autoimmunity, and Cancer. <i>Journal of Immunology Research</i> , 2018, 2018, 1-16.	2.2	56
7	Low number of invariant NKT cells is associated with poor survival in acute myeloid leukemia. <i>Journal of Cancer Research and Clinical Oncology</i> , 2012, 138, 1427-1432.	2.5	47
8	Multiple myeloma-associated amyloidosis is an independent high-risk prognostic factor. <i>Annals of Hematology</i> , 2009, 88, 59-66.	1.8	44
9	The early referral for reduced-intensity stem cell transplantation in patients with Ph1 (+) chronic myelogenous leukemia in chronic phase in the imatinib era: results of the Latin American Cooperative Oncohematology Group (LACOHG) prospective, multicenter study. <i>Bone Marrow Transplantation</i> , 2005, 36, 1043-1047.	2.4	39
10	Intermediate doses of melphalan and dexamethasone are better than vincristine, adriamycin, and dexamethasone (VAD) and polychemotherapy for the treatment of primary plasma cell leukemia. <i>Annals of Hematology</i> , 2002, 81, 362-367.	1.8	36
11	Overexpression of CD158 and NKG2A Inhibitory Receptors and Underexpression of NKG2D and NKp46 Activating Receptors on NK Cells in Acute Myeloid Leukemia. <i>Archives of Medical Research</i> , 2016, 47, 55-64.	3.3	31
12	Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning in Patients with Acute Myelogenous Leukemia Eligible for Conventional Allografting: A Prospective Study. <i>Leukemia and Lymphoma</i> , 2004, 45, 1191-1195.	1.3	28
13	Intravesical rhGM-CSF for the treatment of late onset hemorrhagic cystitis after bone marrow transplant. <i>Bone Marrow Transplantation</i> , 1999, 24, 1307-1310.	2.4	27
14	The C677T Polymorphism of the Methylenetetrahydrofolate Reductase Gene Is Associated with Idiopathic Ischemic Stroke in the Young Mexican-Mestizo Population. <i>Cerebrovascular Diseases</i> , 2010, 29, 454-459.	1.7	27
15	Role of CD4 <sup>+</sup> CD25 <sup>high</sup> Foxp3 <sup>+</sup> CD62L <sup>+</sup> Regulatory T Cells and Invariant NKT Cells in Human Allogeneic Hematopoietic Stem Cell Transplantation. <i>Stem Cells and Development</i> , 2010, 19, 333-340.	2.1	25
16	Clinical relevance of NK, NKT, and dendritic cell dose in patients receiving G-CSF-mobilized peripheral blood allogeneic stem cell transplantation. <i>Annals of Hematology</i> , 2006, 85, 113-120.	1.8	24
17	Multiple myeloma treatment patterns and clinical outcomes in the Latin America Haematology (HOLA) Observational Study, 2008-2016. <i>British Journal of Haematology</i> , 2020, 188, 383-393.	2.5	24
18	INSIGHT MM: a large, global, prospective, non-interventional, real-world study of patients with multiple myeloma. <i>Future Oncology</i> , 2019, 15, 1411-1428.	2.4	23

#	ARTICLE	IF	CITATIONS
19	Prospective randomized clinical trial comparing high-dose ifosfamide+GM-CSF vs high-dose cyclophosphamide+GM-CSF for blood progenitor cell mobilization. Bone Marrow Transplantation, 2000, 25, 1141-1146.	2.4	22
20	Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus. Lupus, 2003, 12, 52-57.	1.6	17
21	Severe functional alterations in vitro in CD34+ cell subpopulations from patients with chronic myeloid leukemia. Leukemia Research, 2004, 28, 639-647.	0.8	16
22	Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia. Tumor Biology, 2017, 39, 101042831773218.	1.8	16
23	CD4+CD25+Lymphocyte and Dendritic Cell Mobilization with Intermediate Doses of Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Donors. Stem Cells and Development, 2005, 14, 310-316.	2.1	15
24	Extramedullary Leukemic Relapses following Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning. International Journal of Hematology, 2005, 82, 262-265.	1.6	14
25	Functional integrity in vitro of hematopoietic progenitor cells from patients with chronic myeloid leukemia that have achieved hematological remission after different therapeutic procedures. Leukemia Research, 2006, 30, 286-295.	0.8	14
26	Maternal obesity associated with increase in natural killer T cells and CD8+ regulatory T cells in cord blood units. Transfusion, 2016, 56, 1075-1081.	1.6	14
27	Peripheral blood mobilization of different lymphocyte and dendritic cell subsets with the use of intermediate doses of G-CSF in patients with non-Hodgkin's lymphoma and multiple myeloma. Annals of Hematology, 2006, 85, 308-314.	1.8	13
28	Autologous peripheral blood stem cell transplantation in multiple myeloma using oral versus I.V. melphalan. Annals of Hematology, 2007, 86, 277-282.	1.8	13
29	Allogeneic Bone Marrow Transplantation for Chronic Myeloid Leukemia. Archives of Medical Research, 2000, 31, 206-209.	3.3	11
30	Donor lymphocyte infusions for relapse of chronic myeloid leukemia after allogeneic stem cell transplantation: prognostic significance of the dose of CD3 + and CD4 + lymphocytes. Annals of Hematology, 2004, 83, 295-301.	1.8	11
31	Src, Akt, NF- $\kappa$ B, BCL-2 and c-IAP1 may be involved in an anti-apoptotic effect in patients with BCR-ABL positive and BCR-ABL negative acute lymphoblastic leukemia. Leukemia Research, 2012, 36, 862-867.	0.8	11
32	Peri-Infusional Adverse Reactions to Rituximab in Patients with Non-Hodgkin's Lymphoma. Archives of Medical Research, 2013, 44, 549-554.	3.3	11
33	Ixazomib-lenalidomide-dexamethasone in routine clinical practice: effectiveness in relapsed/refractory multiple myeloma. Future Oncology, 2021, 17, 2499-2512.	2.4	11
34	Comparative Bioavailability Evaluation of Two Cyclosporine Oral Formulations in Healthy Mexican Volunteers. Archives of Medical Research, 1999, 30, 315-319.	3.3	10
35	Role of CD8 Regulatory T Cells versus Tc1 and Tc17 Cells in the Development of Human Graft-versus-Host Disease. Journal of Immunology Research, 2017, 2017, 1-11.	2.2	10
36	Allogeneic Peripheral Blood Stem Cell Transplantation Using Reduced Intensity Versus Myeloablative Conditioning Regimens for the Treatment of Leukemia. Stem Cells and Development, 2004, 13, 571-578.	2.1	9

#	ARTICLE	IF	CITATIONS
37	In vitro functional alterations in the hematopoietic system of adult patients with acute lymphoblastic leukemia. <i>Leukemia Research</i> , 2007, 31, 83-89.	0.8	9
38	Granulocyte colony-stimulating factor produces a decrease in IFN $\gamma$ and increase in IL-4 when administrated to healthy donors. <i>Journal of Clinical Apheresis</i> , 2010, 25, 181-187.	1.3	9
39	CD133+CD34+ and CD133+CD38+ blood progenitor cells as predictors of platelet engraftment in patients undergoing autologous peripheral blood stem cell transplantation. <i>Transfusion and Apheresis Science</i> , 2012, 46, 239-244.	1.0	9
40	Chronic Lymphocytic Leukemia in the SARS-CoV-2 Pandemic. <i>Current Oncology Reports</i> , 2022, 24, 209-213.	4.0	9
41	Activated Protein C Resistance and Factor V Leiden in Mexico. <i>Clinical and Applied Thrombosis/Hemostasis</i> , 2008, 14, 428-437.	1.7	8
42	Post-treatment improvement of NK cell numbers predicts better survival in myeloma patients treated with thalidomide-based regimens. <i>International Journal of Hematology</i> , 2019, 110, 306-312.	1.6	8
43	In vitro growth of hematopoietic progenitors and stromal bone marrow cells from patients with multiple myeloma. <i>Leukemia Research</i> , 2011, 35, 250-255.	0.8	7
44	Risk Factors for Thrombosis Development in Mexican Patients. <i>Annals of Vascular Surgery</i> , 2015, 29, 1625-1632.	0.9	7
45	Clinical relevance of NKT cells and soluble MIC-A in Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2021, 62, 801-809.	1.3	6
46	Silent Ischemic Heart Disease in a Patient with Necrotizing Glomerulonephritis due to Wegener's Granulomatosis. <i>CardioRenal Medicine</i> , 2012, 2, 218-224.	1.9	4
47	The Latin American experience of allografting patients with severe aplastic anaemia: real-world data on the impact of stem cell source and ATG administration in HLA-identical sibling transplants. <i>Bone Marrow Transplantation</i> , 2017, 52, 41-46.	2.4	4
48	von Willebrand Disease and other hereditary haemostatic factor deficiencies in women with a history of postpartum haemorrhage. <i>Haemophilia</i> , 2020, 26, 97-105.	2.1	4
49	Transplant Status Does Not Impact the Selection of Induction Regimens for Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) in the Insight MM Prospective, Observational Study. <i>Blood</i> , 2018, 132, 3289-3289.	1.4	4
50	Pathophysiology of Alloimmunization. <i>Transfusion Medicine and Hemotherapy</i> , 2020, 47, 152-159.	1.6	3
51	Abo Blood Group, Atherothrombotic Comorbidities, and COVID-19: A Case-Control Study of their Association in the Mexican Population. <i>Archives of Medical Research</i> , 2022, 53, 100-108.	3.3	3
52	IFN- $\gamma$ as Induction and Maintenance Treatment of Patients Newly Diagnosed with Waldenström's Macroglobulinemia. <i>Journal of Interferon and Cytokine Research</i> , 2002, 22, 1013-1016.	1.2	2
53	Genetic susceptibility variants for chronic lymphocytic leukaemia in Mexican mestizos. <i>British Journal of Haematology</i> , 2015, 169, 909-911.	2.5	2
54	IFN- $\gamma$ T Cells Number, CD200, and Flt3 Expression Is Associated with Higher Progression Free Survival in Patients with Chronic Myeloid Leukemia. <i>Archives of Medical Research</i> , 2020, 51, 194-203.	3.3	2

#	ARTICLE	IF	CITATIONS
55	Prescription Patterns of Daratumumab in Patients with Multiple Myeloma in Underprivileged Circumstances: A Multicenter Experience in Mexico. Archives of Medical Research, 2021, 52, 627-634.	3.3	2
56	Malignant fibrous histiocytoma after allogeneic bone marrow transplantation. Bone Marrow Transplantation, 1999, 24, 1029-1031.	2.4	1
57	Determination of Th1/Th2/Th17 Cytokines in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. , 0, , .		1
58	Prognostic Value of CD95, Active Caspase-3, and Bcl-2 Expression in Adult Patients with De Novo Acute Lymphoblastic Leukemia. Archives of Medical Research, 2018, 49, 44-50.	3.3	1
59	A Global Treatment Standard in Multiple Myeloma (MM) Remains Elusive Despite Advances in Care over 15 years: First Results from INSIGHT MM, the Largest Global Prospective, Observational MM Study. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, S247-S248.	0.4	1
60	Rituximab in Warfarin Resistance Treatment in Patients with Thrombophilia Due to Primary Antiphospholipid Syndrome: A Pilot Study.. Blood, 2007, 110, 4001-4001.	1.4	1
61	A tale of two paradigms: fixed duration vs continuous therapy in routine clinical practice: An INSIGHT MM study analysis of duration of therapy. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e4-e5.	0.4	0
62	Efficacy and Safety of Rituximab+CHOP in IR and Maintenance Therapy with Rituximab vs Observation in De Novo Aggressive Non-Hodgkin Lymphoma.. Blood, 2007, 110, 4489-4489.	1.4	0
63	Correlation between FOXP3 Gene Polymorphisms in Donors, and the Severity of Acute Graft-Versus-Host Disease in Patients after Related Allogeneic Stem Cell Transplantation.. Blood, 2007, 110, 3233-3233.	1.4	0
64	Cytogenetics As a Prognostic Factor Of The Overall Survival (OS) Of Mexican Patients With Myelodysplastic Syndrome (MDS). Blood, 2013, 122, 5236-5236.	1.4	0